Glenmark Pharma Q3 profit rises 16%, SAIL exceeds estimates
after close1 source ↓written by the desknot a recommendation
- in Q3 profit
- 16% increase
Glenmark Pharma reported a 16% increase in Q3 profit, reflecting strong operational performance. Meanwhile, SAIL's profit more than doubled, surpassing market expectations amid robust demand. These results come ahead of the Union Budget, potentially influencing market sentiment for related sectors. 📈
• Glenmark's profit growth highlights effective cost management.
• SAIL's performance indicates recovery in the steel sector.
• Anticipation builds for upcoming budget announcements.
Not investment advice. For informational purposes only.